Join to view full profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Join Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 4 invites waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. George Blumenschein Jr., MD is an oncologist in Houston, Texas. He is currently licensed to practice medicine in Texas, Alabama, and Alabama. He is an Associate Professor of Medicine at University Tex Houston.
Education & Training
University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1997 - 2000- University of Texas Health Science Center at HoustonResidency, Internal Medicine, 1994 - 1997
McGovern Medical School at UTHealthClass of 1994
Certifications & Licensure
FL State Medical License 2021 - Present
AZ State Medical License 2023 - 2028
TN State Medical License 2023 - 2028
TX State Medical License 1998 - 2028
GA State Medical License 2023 - 2027
LA State Medical License 2023 - 2027
MS State Medical License 2023 - 2027
American Board of Internal Medicine Medical Oncology- Join now to see all
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ClinicStation, UT MD Anderson Cancer Center, 2013, 2015
Publications & Presentations
PubMed
- 14 citationsImpact of Co-mutations and Transcriptional Signatures in Non-Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial.Marcelo V Negrao, Alvaro G Paula, David Molkentine, Laura Hover, Monique Nilsson
Clinical Cancer Research. 2025-03-17 - 37 citationsA Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve-Mutant Metastatic Non-Small Cell Lung...Xiuning Le, Jyoti D Patel, Elaine Shum, Christina Baik, Rachel E Sanborn
Journal of Clinical Oncology. 2025-02-01 - 139 citationsCTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, Yu Qian, Xin Sun
Nature. 2024-11-01
